Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials-Reference-Cited by-同舟云学术

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Published:2017-01-28 Issue:2 Volume:69 Page:362-375
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Clowse Megan E. B.¹,Wallace Daniel J.²,Furie Richard A.³,Petri Michelle A.⁴,Pike Marilyn C.⁵,Leszczyński Piotr⁶,Neuwelt C. Michael⁷,Hobbs Kathryn⁸,Keiserman Mauro⁹,Duca Liliana¹⁰,Kalunian Kenneth C.¹¹,Galateanu Catrinel¹²,Bongardt Sabine¹³,Stach Christian¹³,Beaudot Carolyn¹⁴,Kilgallen Brian¹⁴,Gordon Caroline¹⁵,

Affiliation:

1. Duke University Medical Center; Durham North Carolina

2. Cedars-Sinai Medical Center; Los Angeles California

3. Northwell Health; New York New York

4. Johns Hopkins University School of Medicine; Baltimore Maryland

5. MedPharm Consulting; Cambridge Massachusetts

6. Poznan University of Medical Sciences; Poznan Poland

7. Alameda County Health System; Oakland California

8. Denver Arthritis Clinic; Denver Colorado

9. Pontifical Catholic University; Porto Alegre Brazil

10. Clinica Neomed; Brasov Romania

11. University of California San Diego School of Medicine; La Jolla